For how we live.
31 articles published between October 13, 2025 and October 18, 2026.
On 13 October the FDA extended Velphoro (sucroferric oxyhydroxide) to children aged 6 to 9 on dialysis and added a 250 mg chewable tablet, widening an iron-based binder previously limited to patients 9 and older.
Across 27 trials and 88,830 people, each 10-mmHg drop in systolic pressure cut cardiovascular events whether or not the kidneys were impaired — while aggressive lowering nudged up short-term markers of kidney decline.
A randomised Asian trial in 130 patients found no efficacy gap between the two drug regimens for active lupus nephritis, but serious infections and all three deaths fell in the mycophenolate group.
ACHIEVE-4 found the non-peptide GLP-1 pill non-inferior to insulin glargine for major cardiac events over two years, with less severe hypoglycaemia but far more gastrointestinal upset. Lilly funded it.
Added to an SGLT2 inhibitor, the aldosterone-synthase inhibitor cut office systolic pressure 7.5 mm Hg and albuminuria about a quarter in 59 adults with CKD. Kidney function dipped slightly; the maker funded it.
The TRACK trial was stopped early for futility. The blood thinner failed to reduce a composite of cardiovascular events, while major bleeding rose by half. Bayer, which makes the drug, was a listed collaborator.
The Global Burden of Disease 2023 study estimates 2.33 billion NCD incident cases and 263 million DALYs across Africa, with high blood pressure the single largest driver of the continent's NCD deaths.
In people with healthy kidneys, trials find high-protein diets do not worsen kidney function. The picture changes for those who already have reduced function, where animal protein may speed decline.
In FINEARTS-HF, 6,001 patients with an ejection fraction of 40% or more had fewer worsening-heart-failure events on finerenone. Cardiovascular deaths were not lower.
Kidney disease is usually silent until it is advanced, and most of it traces to diabetes and high blood pressure. Controlling those two, and getting tested, is the highest-yield protection — not kidney superfoods.
The ESC released updated heart failure guidance plus first-ever guidelines on cardiac rehabilitation and on cardiovascular disease with chronic kidney disease. All three sit behind a paywall.
A meta-analysis of 90,000 people found these diabetes-origin drugs reduced kidney disease progression by 37% and cardiovascular events by 23%, and the benefit was similar in people who did not have diabetes.
High urate levels track with worsening kidney disease, so treating them seemed a logical way to slow it. Two trials that lowered urate with allopurinol found the kidneys declined at the same rate anyway.
Matched against DPP-4 inhibitors, GLP-1 users had slightly more diabetic retinopathy and more retinopathy procedures. Vision impairment and blindness did not differ — and the coding for those is poor.
A regional review finds heat-protection for outdoor workers still leans on limiting work hours, while separate papers link chronic heat exposure among Gulf migrant labourers to a non-traditional form of kidney disease.
In people who already have kidney disease, cutting salt reduced albuminuria by about 36% and lowered blood pressure. High salt also blunts standard kidney-protecting drugs — though long-term outcome trials are missing.
A meta-analysis of 26 trials found creatine raises serum creatinine without markers of kidney injury. Weeks earlier, a Nature Communications paper reported that supplementation promoted metastasis in mice.
The fear that a high-protein diet damages normal kidneys is not supported by the trial evidence. Protein restriction is a therapy studied in people who already have kidney disease — a different question entirely.
Creatinine is muscle waste your kidneys clear; eGFR is an estimate of filtering capacity built from it. A single reading is a snapshot, not a diagnosis — and the equations have limits worth knowing.
Observational studies link higher water intake to healthier kidneys. When a randomised trial coached people with kidney disease to drink more, their filtration fell at the same rate as the control group.
One found PFAS mixtures associated with lower kidney filtration, with blood lipids mediating much of it. The other found the lipid association weaker in people with healthier habits.
Across studies, current NSAID use was tied to about a 73% higher odds of acute kidney injury, more in older people and those with existing kidney disease. The combination with two blood-pressure drugs is the real hazard.
A study of 19,539 patients echoed the randomised CONVINCE trial — but it was observational, and several of its authors work for the dialysis company that owns the data.
There is no trial showing a cleanse product improves kidney function, which already filters blood continuously. One class of herbal kidney remedy is a proven cause of kidney failure and cancer.
The first large-scale policy evaluation of medically tailored meals covers 1,866 recipients across 11 health systems. It is quasi-experimental, not randomised — and that is the finding's main limit.
In the FIND-CKD trial, non-diabetic patients on finerenone lost kidney function at 3.3 versus 4.0 ml/min/1.73 m² a year — a small edge that extends a diabetes drug to a new group.
A national case-crossover study of 236,260 chronic kidney disease deaths finds women, over-65s and people in cooler regions most affected — and projects the burden nearly quadrupling by the 2090s.
A UK Biobank analysis of 96,365 people found a dose-response relationship between lifetime night-shift exposure and cardiovascular-kidney-metabolic disease — amplified in those who also slept short.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
A meta-analysis of eleven depression trials found an average effect below the threshold for clinical importance, with signs of bias favouring creatine. A separate review found no change in kidney filtration.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.